Search Results
Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC
Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC
Dr. Kopetz on the Rationale and Primary Endpoints of the BEACON CRC Study in mCRC
Keynote Lecture 4: The BRAF pathway in CRC?
Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment
Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC
Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC
Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC
Real-World Management of Patients with BRAF-V600E mCRC
Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC
Novel Agents and Targets in Colorectal Cancer
Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer
